Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$0.31 CAD
Change Today -0.015 / -4.69%
Volume 116.3K
As of 3:57 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

theralase technologies inc (TLT) Snapshot

Open
C$0.32
Previous Close
C$0.32
Day High
C$0.32
Day Low
C$0.31
52 Week High
12/23/14 - C$0.78
52 Week Low
10/6/14 - C$0.25
Market Cap
31.9M
Average Volume 10 Days
385.1K
EPS TTM
C$-0.05
Shares Outstanding
104.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for THERALASE TECHNOLOGIES INC (TLT)

Related News

No related news articles were found.

theralase technologies inc (TLT) Related Businessweek News

No Related Businessweek News Found

theralase technologies inc (TLT) Details

Theralase Technologies Inc. designs, develops, manufactures, and markets laser technology used in bio-stimulative and bio-destructive clinical applications. The company engages in the production, marketing, and distribution of TLC-1000 and TLC-2000 laser technology for the treatment of chronic pain, neural muscular-skeletal conditions, and wound healing. It is also involved in the commercialization of the patented TLC-3000 photo dynamic compound technology through pre-clinical scientific research, clinical trials, and technology development in the treatment of cancers for oncological applications and in the destruction of bacteria, viruses, and microbial pathogens; and research and development activities. The company sells its products to licensed healthcare practitioners, such as medical doctors, chiropractors, physical therapists, and athletic therapists in Canada, the United States, and internationally. Theralase Technologies Inc. is headquartered in Toronto, Canada.

theralase technologies inc (TLT) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: C$150.0K
Chief Financial Officer
Total Annual Compensation: C$115.0K
Compensation as of Fiscal Year 2013.

theralase technologies inc (TLT) Key Developments

Theralase Technologies Inc. Achieves Near Complete Destruction of Bladder Cancer in an Animal Model

Theralase Technologies Inc. announced that it has achieved near complete destruction (~98%) of bladder cancer in an animal model. Theralase, in order to optimize the model, relocated it to Princess Margaret Cancer Center, University Health Network ("UHN") under the direction of Dr. Lothar Lilge, Senior Scientist, UHN and Dr. Arkady Mandel, Chief Scientific Officer ("CSO") of the Company. Optimization of both the formulation and purity of the lead drug, TLD-1433, by Sigma Aldridge Fine Chemicals ("SAFC") and the wavelength of laser light used to activate the drug by Theralase resulted in achieving the high cell kill to date. Bladder cancer is the 5th most prevalent cancer in the world (4th in men, 8th in women) resulting in 430,000 new cases worldwide and an estimated 91,000 deaths annually. There has been no new treatment developed for this disease in the last 16 years. The cost to treat a patient with this disease ranges from $100,000 to $200,000. The disease has an 80% recurrence rate. 70% of new bladder cancer cases are early stage disease affecting the inner lining of the bladder (urothelium) and are known as Non-Muscle Invasive Bladder Cancer ("NMIBC"). According to the latest clinical research, 25% of these patients will have a recurrence of the disease within 6 months and a total of 50% recur within 2 years. The standard of care currently is to surgically resect the bladder tumour followed by installation of a bacteria, known as Bacillus-Calmette Guérin ("BCG") into the bladder for high risk patients. The next course of action for these patients, where the standard of care was not effective, is to either repeat the same treatment (surgery and BCG therapy) or to surgically remove the bladder in its entirety with any associated lymph nodes and nearby organs. Theralase is developing an alternative therapy, known as Photo Dynamic Therapy ("PDT"), applicable for the 50% of patients or those who have relapsed within 2 years of treatment. In this form of treatment, Theralase's lead water-soluble PDT drug, TLD-1433, is instilled into the bladder via a plastic tube known as a catheter, allowed to be absorbed into the bladder cancer cells for approximately one hour and then subsequently laser light activated over a period of 30 minutes. The entire procedure could be performed in a surgical suite in less than 3 hours. Theralase is researching the destruction of the entire bladder tumour with only one treatment; however, subsequent treatments could be performed in the future if there ever was a recurrence. The worldwide market for bladder cancer treatment is estimated to be worth more than $20 billion annually, with half of this population having a need for an alternative to their standard of care within 2 years.

Theralase Technologies Inc. Announces Executive Appointments

Theralase Technologies Inc. announced that it has appointed an experienced sales and marketing team to launch its next generation therapeutic laser. David Smith, Director of Sales, David has demonstrated success in previous senior sales positions with Eli Lilly, Baxter and Philips Healthcare. Alan Chan, Director of Marketing, Alan was a pioneer in the creation of the medical aesthetics market, when he led the launch of Botox. Alan possesses the experience and vision to help Theralase command a dominant role in the therapeutic laser market with the launch of the TLC-2000.

Theralase Technologies Inc. to Launch its Next Generation Therapeutic Laser

Theralase Technologies Inc. announced that it has appointed an experienced sales and marketing team to launch its next generation therapeutic laser. The TLC-2000 therapeutic laser with patented Cell SensingTM technology, has the unique ability of being able to sense injured tissue and then simultaneously deliver a precise dose of laser energy to the area healing it, safer, faster and more effectively than any other competitive product on the market. Theralase expects that this next generation technology will revolutionize the therapeutic laser industry by providing healthcare practitioners with a technology that possesses the repeatability and reproducibility that has been lacking in the field, allowing Theralase the opportunity to catapult for the first time into mainstream medicine.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TLT:CN C$0.31 CAD -0.015

TLT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TLT.
View Industry Companies
 

Industry Analysis

TLT

Industry Average

Valuation TLT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 17.3x
Price/Book 3.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 16.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THERALASE TECHNOLOGIES INC, please visit www.theralase.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.